<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR522.html">Part 522
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 522.955  Florfenicol.
                            </h3>
                            <p class="depth0"><em>(a)</em> Specifications. Each milliliter of solution contains:</p><p class="depth0"><em>(1)</em> 300 milligrams (mg) florfenicol in the inactive vehicles 2-pyrrolidone and triacetin.</p><p class="depth0"><em>(2)</em> 300 mg florfenicol in the inactive vehicles n-methyl-2-pyrrolidone, propylene glycol, and polyethylene glycol.</p><p class="depth0"><em>(3)</em> 300 mg florfenicol in the inactive vehicles 2-pyrrolidone and glycerol formal.</p><p class="depth0"><em>(b)</em> Sponsors. See sponsor numbers in Sec. 510.600(c) of this chapter:</p><p class="depth0"><em>(1)</em> No. 000061 for use of product described in paragraph (a)(1) as in paragraph (d)(1)(i); and</p><p class="depth0"><em>(2)</em> Nos. 000061 and 000859 for use of product described in paragraph (a)(2) as in paragraph (d)(1)(ii).</p><p class="depth0"><em>(3)</em> No. 055529 for use of product described in paragraph (a)(3) as in paragraph (d)(1)(ii).</p><p class="depth0"><em>(c)</em> Related tolerances. See Sec. Sec. 500.1410 and 556.283 of this chapter.</p><p class="depth0"><em>(d)</em> Conditions of use--(1) Beef and non-lactating dairy cattle--(i) 300 mg per milliliter (mL) florfenicol in the inactive vehicles 2-pyrrolidone and triacetin:</p><p class="depth0"><em>(A)</em> Amount. 40 mg/kilogram (kg) body weight as a single subcutaneous injection.</p><p class="depth0"><em>(B)</em> Indications for use. For treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle.</p><p class="depth0"><em>(C)</em> Limitations. Animals intended for human consumption must not be slaughtered within 44 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(ii)</em> 300 mg/mL florfenicol in the inactive vehicles n-methyl-2- pyrrolidone, propylene glycol, and polyethylene glycol, or in 2-pyrrolidone and glycerol formal:</p><p class="depth0"><em>(A)(1)</em> Amount. 20 mg/kg of body weight as an intramuscular injection. A second dose should be administered 48 hours later. Alternatively, 40 mg/kg

of body weight as a single subcutaneous injection may be used.</p><p class="depth0"><em>(2)</em> Indications for use. For treatment of BRD associated with Mannheimia (Pasteurella) haemolytica, P. multocida, and Haemophilus somnus. For treatment of bovine interdigital phlegmon (foot rot, acute interdigital necrobacillosis, infectious pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.</p><p class="depth0"><em>(B)(1)</em> Amount. 40 mg/kg of body weight as a single subcutaneous injection.</p><p class="depth0"><em>(2)</em> Indications for use. For control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica, P. multocida, and Haemophilus somnus.</p><p class="depth0"><em>(C)</em> Limitations. Animals intended for human consumption must not be slaughtered within 28 days of the last intramuscular treatment. Animals intended for human consumption must not be slaughtered within 33 days of subcutaneous treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(2)</em> [Reserved]
[73 FR 21041, Apr. 18, 2008, as amended at 74 FR 66574, Dec. 16, 2009; 79 FR 18158, Apr. 1, 2014; 79 FR 53136, Sept. 8, 2014; 80 FR 61296, Oct. 13, 2015; 80 FR 76386, Dec. 9, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
